Coeptis Therapeutics(COEP.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Coeptis Therapeutics
COEP.US
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its product portfolio and rights are licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, natural killer cell therapy technology. Its product pipeline consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy; and SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological and solid tumors.
1.880 T
COEP.USMarket value -Rank by Market Cap -/-

Financial Score

19/01/2026 Update
C
BiotechnologyIndustry
Industry Ranking143/398
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-163.12%E
    • Profit Margin-2472.91%E
    • Gross Margin80.98%A
  • Growth ScoreC
    • Revenue YoY0.00%C
    • Net Profit YoY-7.55%C
    • Total Assets YoY58.35%A
    • Net Assets YoY119.11%A
  • Cash ScoreC
    • Cash Flow Margin-4.04%D
    • OCF YoY0.00%C
  • Operating ScoreE
    • Turnover0.04E
  • Debt ScoreA
    • Gearing Ratio23.02%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Nasdaq Warns Coeptis Therapeutics Over Missed Annual Shareholder Meeting Deadline

    Coeptis Therapeutics Holdings Inc. has been notified by Nasdaq for failing to hold its annual shareholder meeting within the required timeframe, leading to noncompliance with listing rules. The company has until February 26, 2026, to submit a compliance plan, with a potential extension until June 29, 2026. Coeptis plans to hold its annual meeting on January 30, 2026, which it believes will address the compliance issue.

    Reuters·
    US
    COEP
    -7.18%
    Reuters·
    US
    COEP
    -7.18%

    Coeptis Therapeutics S-4 Declared Effective by SEC, Proxy Mailing Begins in Anticipation of the Merger Transaction with Z Squared | COEP Stock News

    Coeptis Therapeutics announced that its S-4 registration statement for the merger with Z Squared has been declared effective by the SEC. The definitive proxy statement will be mailed to shareholders ahead of the Annual/Special Meeting on January 30, 2026. The combined company has applied for Nasdaq listing, but approval is pending. If not approved, shares will trade on OTC Markets. Coeptis focuses on innovative biopharmaceuticals, while Z Squared operates in cryptocurrency mining. This announcement does not constitute a solicitation or offer to sell securities.

    StockTitan·
    US
    COEP
    -7.18%
    StockTitan·
    US
    COEP
    -7.18%

    Coeptis Therapeutics (NASDAQ:COEP) Stock Price Down 3.6% - Time to Sell?

    Coeptis Therapeutics (NASDAQ:COEP) shares fell 3.6% during mid-day trading, with a significant increase in trading volume. Analysts have issued a "Sell" rating, and the stock has a market cap of $80.37 million. Despite recent hedge fund interest, Coeptis Therapeutics is not among the top recommended stocks by analysts.

    Market Beat·
    US
    COEP
    -7.18%
    Market Beat·
    US
    COEP
    -7.18%

    Coeptis Therapeutics (NASDAQ:COEP) Stock Price Up 12.2% - What's Next?

    Coeptis Therapeutics (NASDAQ:COEP) stock rose 12.2% to $17.00, with trading volume up 92% from the average. Despite the rise, Weiss Ratings reaffirmed a 'sell' rating. The company, with a market cap of $90.78 million, develops cell therapy platforms for cancer. Institutional investors own 13.88% of the stock. Yorkville Advisors recently acquired a new stake. Analysts suggest other stocks may be better buys.

    Market Beat·
    US
    COEP
    -7.18%
    Market Beat·
    US
    COEP
    -7.18%

    Coeptis Therapeutics (NASDAQ:COEP) Stock Price Up 0.3% - Here's Why

    Coeptis Therapeutics (NASDAQ:COEP) saw a 0.3% increase in stock price, trading at $15.04 after reaching a high of $15.28. Trading volume was down 72% from the average, with 12,602 shares exchanged. Analysts maintain a consensus "Sell" rating, with Weiss Ratings reiterating a "sell (e+)" rating. The company reported a quarterly EPS of ($1.17) and revenue of $0.20 million. Coeptis focuses on developing cell therapy platforms for cancer treatment, with a market cap of $72.49 million and a debt-to-equity ratio of 0.02.

    Market Beat·
    US
    COEP
    -7.18%
    Market Beat·
    US
    COEP
    -7.18%
    © 2026 Longbridge｜Disclaimer